Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-Label Study of LNP3794 (BI3011441) in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors

NCT05187858 is registered in ClinicalTrials.gov with Lupin Ltd. as lead sponsor.

NCT NCT05187858
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05187858 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-Label Study of LNP3794 (BI3011441) in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors
Lead sponsor
Lupin Ltd.
Phase
Phase 1
Overall status
Completed
Start date
September 22, 2020
Completion date
June 30, 2022
Enrollment
15 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

nras/kras mutated advanced or metastatic refractory solid tumors